Document 9JBznjbqKQq9j4ZJzmk5DB0op

R20239 UNI ROYAL, Inc World Headquarters (Location) November 2, 1983 To: Bob Hall Palnesville Subject: Upda on VC Epidemiological Study Enclosed is the latest information on the VC update from CMA. Since we are completely out of the VC and PVC businesses, I am no longer one of the Research Coordinators. However, I am on the panel so we will continue to have full access to all the data. In Table 1 your plant is No. 27. I notice that your plant was one of the first to return the worksheets as well as one that had the most complete records (Table 4). Once the proposal for the next step is approved I should think that the computer analysis would move rapidly. However, many questions will arise and we will want to look at the data in many ways before a final report is issued. 1 have said from the beginning that VC presents us with one of the best opportunities to compare animal vs. human ca rcinogenicity. (1) A large number of people exposed. (2) At a wide range of concentrations. (3) Over a long time period. There will be undoubtedly a great deal of attention focused by the scientific community on other types of cancer such as brain tumors once the report is issued since Maltonis study did find excesses in the animal studies. a. WDH/mcw cc: B. R. Leach E. J. Sowinski v'j. D. Forbes, M.D. file (2) W. D. Harris INTERCOMPANY CORRESPONDENCE